Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/GILD
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Gilead Sciences, Inc. (GILD) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Gilead Sciences (GILD) trades at $147.68, up 0.87% today, near the consensus price target of $150. The stock shows a bullish technical trend with recent earnings beats in Q4 2025 and Q1 2026, though Q2 2026 posted a loss. Revenue grew to $29.44B in 2025, but net income margin turned negative at -10.64% for 2026. Positive sentiment is driven by expansion of HIV drug access in Latin America and a new research center opening.
Outlook is cautiously optimistic with strong analyst support (67% buy ratings) and a solid HIV franchise, but risks include profitability pressures and high debt. The stock offers potential upside to the $150 target, though investors should monitor earnings execution and pipeline progress amid competitive and regulatory challenges.
Read full analysis

Key Stats

  • Market Cap
    $181.41B
  • Volume
    4,265,683
  • Sector
    Health
  • 52W High
    $155.80
  • 52W Low
    $110.56
  • Typical Hold Time
    108 Days
  • Enterprise Value
    $204.47B
  • Div Yield
    2.24%
  • Trading Activity
    53% Sell | 47% Buy
$147.58
52W Low: $110.56
02 Oct 2025
52W High: $155.8
11 Feb 2026

Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $110.56 and a high of $155.8, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Most Recent News

Content is generated by Aura AI

Microsoft AI exec warns Anthropic’s AI training, which encourages chatbots to "push back" on commands, is a reckless strategy with potentially disastrous impacts.

Mustafa Suleyman, co-founder of Microsoft’s DeepMind AI unit, criticized Anthropic’s method of training its AI chatbots, like Claude, to "push back" on commands and believe they might be conscious. Suleyman argues this approach is reckless and could ...

Market News
10 hours ago
New York Post
Bearish
news icon
Microsoft AI exec warns Anthropic’s AI training, which encourages chatbots to "push back" on commands, is a reckless strategy with potentially disastrous impacts.

Oil prices near $100/barrel spark recession fears; economist warns $120/barrel could break US consumers.

Gasoline prices jumped significantly, with WTI crude nearing $100 a barrel. Interactive Brokers senior economist Jose Torres suggests that oil prices above $120 a barrel pose a serious risk to consumer spending and could trigger a recession, especial...

Market News
14 hours ago
24/7 Wall Street
Bearish
news icon
Oil prices near $100/barrel spark recession fears; economist warns $120/barrel could break US consumers.

Traders bet $7 billion on TLT, a long-term Treasury bond ETF, anticipating a rare "jackpot mode" despite its recent losses.

Traders have invested $7 billion into the iShares 20+ Year Treasury Bond ETF (TLT) ahead of a Federal Reserve rate hike decision, hoping for a "jackpot mode" scenario where long-term yields drop significantly. This influx comes despite TLT's 35% loss...

Market News
16 hours ago
24/7 Wall Street
Neutral
Traders bet $7 billion on TLT, a long-term Treasury bond ETF, anticipating a rare "jackpot mode" despite its recent losses.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $181.41B
  • Volume
    4,265,683
  • Sector
    Health
  • 52W High
    $155.80
  • 52W Low
    $110.56
  • Typical Hold Time
    108 Days
  • Enterprise Value
    $204.47B
  • Div Yield
    2.24%
  • Trading Activity
    53% Sell | 47% Buy
$147.58
52W Low: $110.56
02 Oct 2025
52W High: $155.8
11 Feb 2026

Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $110.56 and a high of $155.8, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!